Clinical impacts of frailty, poor performance status, and advanced age in carfilzomib-containing treatment for relapsed/refractory multiple myeloma: post hoc investigation of the KOTOSG multicenter pilot prospective observational study-Reference-Cited by-同舟云学术

Clinical impacts of frailty, poor performance status, and advanced age in carfilzomib-containing treatment for relapsed/refractory multiple myeloma: post hoc investigation of the KOTOSG multicenter pilot prospective observational study

Published:2022-01-24 Issue:3 Volume:115 Page:350-362
ISSN:0925-5710
Container-title:International Journal of Hematology
language:en
Short-container-title:Int J Hematol

Author:

Kawaji-Kanayama Yuka,Muramatsu Ayako,Sasaki Nana,Shimura Kazuho,Kiyota Miki,Fuchida Shinichi,Isa Reiko,Fujino Takahiro,Matsumura-Kimoto Yayoi,Tsukamoto Taku,Chinen Yoshiaki,Mizutani Shinsuke,Nakao Mitsushige,Kaneko Hiroto,Kawata Eri,Hirakawa Koichi,Takahashi Ryoichi,Shimazaki Chihiro,Uchiyama Hitoji,Uoshima Nobuhiko,Shimura Yuji,Kobayashi Tsutomu,Taniwaki Masafumi,Kuroda Junya^ORCID,

Funder

Ono Pharmaceutical

Publisher

Springer Science and Business Media LLC

Subject

Hematology

Link

https://link.springer.com/content/pdf/10.1007/s12185-021-03262-z.pdf

Reference44 articles.

1. Pulte D, Gondos A, Brenner H. Improvement in survival of older adults with multiple myeloma: results of an updated period analysis of SEER data. Oncologist. 2011;16(11):1600–3.

2. Stewart AK, Rajkumar SV, Dimopoulos MA, Masszi T, Spicka I, Oriol A, et al. Carfilzomib, lenalidomide, and dexamethasone for relapsed multiple myeloma. N Engl J Med. 2015;372:142–52.

3. Siegel DS, Dimopoulos MA, Ludwig H, Facon T, Goldschmidt H, Jakubowiak A, et al. Improvement in overall survival with carfilzomib, lenalidomide, and dexamethasone in patients with relapsed or refractory multiple myeloma. J Clin Oncol. 2018;36(8):728–34.